Drug Profile
Cofetuzumab pelidotin - Abbvie/Pfizer
Alternative Names: ABBV-647; PF-06647020; PF-6647020; PF-7020; PTK7-ADCLatest Information Update: 06 Feb 2024
Price :
$50
*
At a glance
- Originator Stemcentrx
- Developer AbbVie; Pfizer; Stemcentrx
- Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates
- Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Non-small cell lung cancer; Solid tumours; Triple negative breast cancer
Most Recent Events
- 06 Feb 2024 Discontinued - Phase-I for Solid tumours (Late-stage disease, Second-line therapy or greater) in Spain (IV) prior to February 2024
- 02 Feb 2024 Discontinued - Phase-I for Non-small cell lung cancer (Recurrent, Second-line therapy or greater) in Japan, Israel, Taiwan, Spain, South Korea (IV) prior to February 2024
- 02 Feb 2024 Discontinued - Phase-I for Solid tumours (Late-stage disease, Second-line therapy or greater) in USA (IV) prior to February 2024